Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
endocrine therapy
hormone receptor
meta-analysis
metastatic breast cancer
systematic review
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Mar 2021
22 Mar 2021
Historique:
received:
09
02
2021
revised:
09
03
2021
accepted:
17
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
A precise assessment of the efficacy of first-/second-line endocrine therapies (ET) ± target therapies (TT) in clinically-relevant subgroups of hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) has not yet been conducted. To improve our current knowledge and support clinical decision-making, we thus conducted a systematic literature search to identify all first-/second-line phase II/III randomized clinical trials (RCT) of currently approved or most promising ET ± TT. Then, we performed a meta-analysis to assess progression-free (PFS) and/or overall survival (OS) benefit in several clinically-relevant prespecified subgroups. Thirty-five RCT were included (17,595 patients). Pooled results show significant reductions in the risk of relapse or death of 26-41% and 12-27%, respectively, depending on the clinical subgroup. Combination strategies proved to be more effective than single-agent ET (PFS hazard ratio (HR) range for combinations: 0.60-0.65 vs. HR range for single agent ET: 0.59-1.37; OS HR range for combinations: 0.74-0.87 vs. HR range for single agent ET: 0.68-0.98), with CDK4/6-inhibitors(i) + ET being the most effective regimen. Single agent ET showed comparable efficacy with ET+TT combinations in non-visceral (
Identifiants
pubmed: 33810205
pii: cancers13061458
doi: 10.3390/cancers13061458
pmc: PMC8004645
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Ministry of University and Research (MIUR)
ID : 2017EKMFTN_006
Organisme : European Society for Medical Oncology
ID : ESMO Fellowship 2020 - Translational
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Eur J Cancer. 2003 Nov;39(16):2318-27
pubmed: 14556923
J Natl Cancer Inst. 2014 Jan;106(1):djt337
pubmed: 24317176
Breast Care (Basel). 2017 Oct;12(5):290-294
pubmed: 29234247
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Breast Cancer Res Treat. 2012 Nov;136(2):503-11
pubmed: 23065000
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Lancet. 2017 Dec 17;388(10063):2997-3005
pubmed: 27908454
J Clin Oncol. 2002 Aug 15;20(16):3386-95
pubmed: 12177098
J Clin Oncol. 2013 Jan 10;31(2):195-202
pubmed: 23233719
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
JNCI Cancer Spectr. 2018 Nov;2(4):pky062
pubmed: 30627694
J Clin Oncol. 2001 Jul 15;19(14):3357-66
pubmed: 11454883
J Clin Epidemiol. 2000 May;53(5):477-84
pubmed: 10812319
J Natl Cancer Inst. 2000 Jun 7;92(11):903-11
pubmed: 10841825
Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
PLoS Med. 2020 Jan 31;17(1):e1003019
pubmed: 32004320
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Curr Med Res Opin. 2014 Jun;30(6):1007-16
pubmed: 24490834
J Clin Oncol. 2008 Apr 1;26(10):1664-70
pubmed: 18316794
Cancer Res Treat. 2011 Jun;43(2):89-95
pubmed: 21811424
Breast Cancer Res Treat. 2017 Nov;166(1):167-177
pubmed: 28752187
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Ann Oncol. 2021 Feb;32(2):197-207
pubmed: 33186740
Breast Cancer Res Treat. 2013 Jun;139(2):441-51
pubmed: 23715630
J Hematol Oncol. 2018 Jun 11;11(1):80
pubmed: 29891002
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
J Clin Oncol. 2008 Oct 20;26(30):4883-90
pubmed: 18794551
J Clin Oncol. 2018 Jun 1;36(16):1556-1563
pubmed: 29664714
Lancet Oncol. 2019 Oct;20(10):1360-1369
pubmed: 31494037
ESMO Open. 2020 Aug;5(4):
pubmed: 32847835
Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30
pubmed: 20938664
Breast. 2017 Feb;31:114-120
pubmed: 27837704
Lancet Oncol. 2017 Apr;18(4):545-554
pubmed: 28238593
J Clin Oncol. 2012 Aug 1;30(22):2718-24
pubmed: 22565002
J Clin Oncol. 2021 Oct 1;39(28):3171-3181
pubmed: 34357781
Adv Ther. 2013 Oct;30(10):870-84
pubmed: 24158787
BMJ. 2006 Sep 16;333(7568):597-600
pubmed: 16974018
Eur J Cancer. 2018 Nov;103:127-136
pubmed: 30223226
Ann Oncol. 2016 Feb;27(2):256-62
pubmed: 26578730
J Clin Oncol. 2000 Apr;18(7):1399-411
pubmed: 10735887
Breast Cancer Res Treat. 2015 Jul;152(1):95-117
pubmed: 26044370
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
J Natl Cancer Inst. 2020 Nov 1;112(11):1089-1097
pubmed: 32407488
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
J Clin Oncol. 2001 May 15;19(10):2596-606
pubmed: 11352951
J Clin Oncol. 2000 Nov 15;18(22):3748-57
pubmed: 11078487
Breast Cancer (Auckl). 2012;6:159-71
pubmed: 23133315
J Clin Epidemiol. 2001 Oct;54(10):1046-55
pubmed: 11576817
N Engl J Med. 2012 Aug 2;367(5):435-44
pubmed: 22853014
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
J Clin Oncol. 2002 Aug 15;20(16):3396-403
pubmed: 12177099
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Breast Cancer Res Treat. 2014 Dec;148(3):553-61
pubmed: 25381136
Lancet Oncol. 2013 Sep;14(10):989-98
pubmed: 23902874
Lancet Oncol. 2016 Jun;17(6):811-821
pubmed: 27155741
J Clin Oncol. 2015 Nov 10;33(32):3781-7
pubmed: 26371134
J Clin Oncol. 2010 Oct 20;28(30):4594-600
pubmed: 20855825
J Clin Oncol. 2013 Jun 10;31(17):2128-35
pubmed: 23650416
J Clin Oncol. 2004 May 1;22(9):1605-13
pubmed: 15117982
J Clin Oncol. 2009 Sep 20;27(27):4530-5
pubmed: 19704066
J Clin Oncol. 2000 Nov 15;18(22):3758-67
pubmed: 11078488
J Clin Oncol. 2012 Jun 1;30(16):1919-25
pubmed: 22370325
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Am J Clin Oncol. 2003 Jun;26(3):317-22
pubmed: 12796608
JAMA Oncol. 2016 Oct 01;2(10):1310-1315
pubmed: 27532364
Clin Breast Cancer. 2019 Dec;19(6):e701-e716
pubmed: 31427171
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880